Tasnim Khessib

Tasnim Khessib

Auto-generated profile, based on publicly available information

Tasnim Khessib

Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford Health Care; 300 Pasteur Drive, Palo Alto, CA 94305

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2024 in Seminars in Nuclear Medicine
Verified
Journal Article
Closed access
TKTasnim Khessib
Tasnim Khessib
PJPriyanka Jha
Priyanka Jha
GDGuido Alejandro Davidzon
Guido Alejandro Davidzon
AIAndrei Iagaru
Andrei Iagaru
JSJagruti Shah
Jagruti Shah

1 February 2023 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
TKTasnim Khessib
Tasnim Khessib
BFBenjamin Md Franc
Benjamin Md Franc
EYEric Yang
Eric Yang
FMFarshad Moradi
Farshad Moradi
A 68-year-old man with a history of pulmonary adenocarcinoma on maintenance pembrolizumab presented for surveillance imaging. 18F-FDG PET/CT demonstrated new ill-defined right retroperitoneal and presacral soft tissue stranding with associated FDG uptake suggestive of inflammation. Biopsy results revealed fibroadipose tissue with extensive lymphoplasmacytic inflammation concerning for immunotherapy-related toxicity. The patient was subsequently taken off pembrolizumab, which he had been on for approximately 3 years. Recognition of immunotherapy-related adverse effects and how they can manifest on 18F-FDG PET/CT is important for prompt cessation of treatment.

1 July 2022 in Current Problems in Diagnostic Radiology
Verified
Journal Article
Closed access
TKTasnim Khessib
Tasnim Khessib
MIMalak Itani
Malak Itani
DHDaniel S Hippe
Daniel S Hippe
GAGensuke Akaike
Gensuke Akaike
MBMohammed Bermo
Mohammed Bermo
FBFatemeh Behnia
Fatemeh Behnia

30 August 2023 in Radiology Case Reports
Verified
Journal Article
Open access
TKTasnim Khessib
Tasnim Khessib
SKSamy Khessib
Samy Khessib
GBGerald J. Berry
Gerald J. Berry
MAMari Aparici
Mari Aparici
Neuroendocrine tumor (NET) metastasis to the thyroid is rare, and its presentation as the first manifestation of primary malignancy elsewhere is even more uncommon. We present a case of a 41-year-old female who underwent biopsy of enlarging thyroid nodules with findings suspicious for medullary thyroid cancer (MTC). Subsequent thyroidectomy demonstrated NET of unknown primary in the left lower lobe. Immediate workup with 68Ga-DOTATATE-PET/CT revealed abnormal somatostatin receptor (SR) expressing lesions in the liver, right cervical nodes, thoracic paravertebral soft tissue, precoccygeal soft tissue, and right acetabulum concerning for sites of neuroendocrine malignancy. Due to disease progression while on octreotide injections, a decision was made at the multidisciplinary NET board for the patient to receive peptide receptor radionuclide therapy (PRRT) which includes 4 cycles of 77Lu-DOTATATE (Lutathera). The patient had no side effects nor toxicities during the 8 months of PRRT and achieved a partial treatment response in the early post-treatment scan at 6 weeks. This case illustrates the importance of distinguishing NET metastasis to the thyroid from MTC to ensure appropriate workup and treatment as well as predict the response of neuroendocrine malignancies to PRRT based on the visualized overexpression of SR in the SR-PET scans, despite the organ of origin.